当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Neha Sharma*
Aptamers are single-stranded molecules of relatively short DNA or RNA (20–60 nucleotides) that bind to a variety of targets with high affinity and specificity. Aptamers are frequently referred to as “synthetic antibodies,” despite the fact that they are simpler to acquire, less costly to manufacture, and more versatile than antibodies in several ways. Since their inception in 1990, Aptamers have been the subject of a steady increase in publications. The focus of this account was on recent original research publications, or those published between April 2019 and the time this account was written in 2020. Relevance-ranking of articles was found by conducting a Google Scholar search of this recent literature. There was no new aptamer selection methods included. Representative examples of each of the nine categories of applications are provided. Last but not least, an outlook is provided that focuses on application performance factors such as “faster, better, and cheaper” as the primary drivers for upcoming innovations in aptamer applications.